
    
      A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus
      Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced
      Triple-Negative Breast Cancer.
    
  